The New Myth

[1]  W. Brouwer,et al.  Reconciliation of economic concerns and health policy , 2012, PharmacoEconomics.

[2]  H. Gravelle,et al.  Discounting in economic evaluations: stepping forward towards optimal decision rules. , 2007, Health economics.

[3]  A. Gafni,et al.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.

[4]  Jeff Richardson,et al.  Can we estimate the 'social' value of a QALY? Four core issues to resolve. , 2005, Health Policy.

[5]  M. Drummond,et al.  Inclusion of cost effectiveness in licensing requirements of new drugs : The fourth hurdle , 2017 .

[6]  Alan Williams,et al.  What Could be Nicer than NICE , 2004 .

[7]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  R. Cookson,et al.  Equity in health , 2000 .

[9]  J. Quiggin,et al.  Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? , 1999, Journal of health economics.

[10]  A. Williams,et al.  Intergenerational equity: an exploration of the 'fair innings' argument. , 1997, Health economics.

[11]  John E. Roemer,et al.  Interpersonal Comparisons of Well-Being , 1991 .

[12]  Peter J. Hammond,et al.  Interpersonal Comparisons of Well-being: Interpersonal comparisons of utility: Why and how they are and should be made , 1990 .